💰DeepTech Briefing - Where Smart Money Is Flowing in 2025

Your Weekly Shortcut to Deeptech Investing—Exclusive Trends & Startup Reports for VCs & Angels in Just 5 Minutes

This Week’s 5-Minute Read

Deeptech funding is rebounding, but VCs and angels are shifting their strategies. Where is smart money flowing in 2025? This week, I’m breaking down:

✅ Market Intelligence: The AI, biotech & quantum sectors attracting fresh VC capital
✅ Investor Playbook: How VCs are structuring deeptech investments to manage risk
✅ Dealflow & Startup Report: One deeptech startup that just raised $50M—and why top investors are backing it

Follow the Money. Stay Ahead. Invest Smart.

Let’s dive in.

---

1️⃣

🔑 Insider Access:

Deeptech investment is shifting as VCs & angels are prioritizing commercialization-ready startups over pure R&D.

🔹 AI & Automation: The AI funding frenzy is cooling, but sector-specific AI applications in biotech, finance, and industrial automation are attracting capital.

🔹 Quantum Computing: Government-backed investment is growing, but VCs are favoring quantum software & cybersecurity over quantum hardware plays.

🔹 Biotech & Life Sciences: Investors are moving into AI-powered biotech & synthetic biology, but only backing startups with clear paths to regulatory approval.

Why it matters: The deeptech investment cycle is shifting toward commercial applications. Investors are looking for revenue-ready startups, not just breakthrough science.

🔗 Premium Members Get the Full Deeptech Investment Breakdown—Join Now

---

2️⃣

🔑 Insider Access:

With high capital intensity and long commercialization timelines, deeptech has always been a high-risk, high-reward category. But VCs & angels are using new strategies to manage that risk.

How VCs are de-risking deeptech:
✅ Co-investments with governments & corporates to secure non-dilutive funding
✅ Strategic use of ETFs & public market exposure to hedge against private market risk
✅ Backing deeptech startups with active revenue streams & corporate partnerships

Want to see the full strategy breakdown? Premium members get:
📈 How top investors are structuring their portfolios
🚀 The biggest risks investors are watching in 2025
📊 Deep dive into how VCs are selecting deeptech investments

🔗 Unlock the Full Investor Playbook Inside Premium

---

3️⃣

🔑 Insider Access:

One of Europe’s most promising AI-driven biotech startups, Owkin, has just secured a $50M Series B to revolutionize drug discovery and precision medicine. Investors are backing its federated learning AI model, which cuts drug R&D costs by 40% and ensures privacy-compliant collaboration in pharmaceutical research.

Why It Matters: Owkin’s strong pharma partnerships, dual revenue streams, and expansion into global markets position it as a high-growth, commercialization-ready deeptech play.

Inside This Report:
📊 Market positioning & competitive landscape – How Owkin stacks up against U.S. competitors.
⚠️ Key risks investors should watch – From AI regulation to pharma reliance.
💡 Exit strategy scenarios – IPO, M&A, or a tech giant acquisition?

🔗 Read the full Startup Breakdown Analysis Inside Premium

---

Final Thought

Deeptech investments are shifting. The best-funded startups in 2025 will be commercialization-driven, not just tech-driven.

💬 Which deeptech sector do you see gaining the most traction this year? Message me and let me know!

---

Stay Connected! 📲

Don’t miss out on daily updates and exclusive content—join my Investors Community on Instagram, LinkedIn, and Facebook.

---

🌟 Join me in my mission to impact 1M lives!

Subscribe to my newsletter to make a difference together!

Stay ahead,

Eden Djanashvili
Author Invest Deeptech